The Liquid Biopsy Turns Ten: Blood Tests That Find Cancer Early
A decade after the first commercial ctDNA tests, blood-based screening is approaching the sensitivity to catch stage I cancer.
Fragments in the bloodstream
Circulating tumour DNA lets a single draw flag multiple cancer types years before symptoms. Sensitivity at early stages has gone from ~30% to past 70% on multi-cancer panels.
The remaining gap is specificity — false positives still send healthy people into invasive workups.
FAQs
What is "The Liquid Biopsy Turns Ten: Blood Tests That Find Cancer Early" about?
A decade after the first commercial ctDNA tests, blood-based screening is approaching the sensitivity to catch stage I cancer.
Who wrote "The Liquid Biopsy Turns Ten: Blood Tests That Find Cancer Early"?
"The Liquid Biopsy Turns Ten: Blood Tests That Find Cancer Early" was written by Demo Admin. Building incoffeed — a daily editorial on tech, AI, fintech and business. Co-founder & editor.
How long does it take to read "The Liquid Biopsy Turns Ten: Blood Tests That Find Cancer Early"?
8 min — that's the estimated reading time for "The Liquid Biopsy Turns Ten: Blood Tests That Find Cancer Early" at an average pace.
Where can I find more stories like "The Liquid Biopsy Turns Ten: Blood Tests That Find Cancer Early"?
More Biotech & Health coverage lives under the “Biotech & Health” topic on incoffeed. You can also react to this story and join the discussion below — the feed keeps serving related reads as you scroll.